CA2057456A1 - Produit pharmaceutique contre la depression - Google Patents

Produit pharmaceutique contre la depression

Info

Publication number
CA2057456A1
CA2057456A1 CA2057456A CA2057456A CA2057456A1 CA 2057456 A1 CA2057456 A1 CA 2057456A1 CA 2057456 A CA2057456 A CA 2057456A CA 2057456 A CA2057456 A CA 2057456A CA 2057456 A1 CA2057456 A1 CA 2057456A1
Authority
CA
Canada
Prior art keywords
anti depression
pharmaceutical
depression pharmaceutical
nicotinamide
adenine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2057456A
Other languages
English (en)
Other versions
CA2057456C (fr
Inventor
Jorg Birkmayer
Walther Birkmayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2057456A1 publication Critical patent/CA2057456A1/fr
Application granted granted Critical
Publication of CA2057456C publication Critical patent/CA2057456C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002057456A 1991-01-04 1991-12-10 Produit pharmaceutique contre la depression Expired - Fee Related CA2057456C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4100361A DE4100361C1 (fr) 1991-01-04 1991-01-04
DEP4100361.6 1991-01-04

Publications (2)

Publication Number Publication Date
CA2057456A1 true CA2057456A1 (fr) 1992-07-05
CA2057456C CA2057456C (fr) 1996-02-06

Family

ID=6422686

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002057456A Expired - Fee Related CA2057456C (fr) 1991-01-04 1991-12-10 Produit pharmaceutique contre la depression

Country Status (15)

Country Link
EP (1) EP0493861B1 (fr)
JP (1) JP2519148B2 (fr)
AT (1) ATE148991T1 (fr)
AU (1) AU631755B2 (fr)
BR (1) BR9105183A (fr)
CA (1) CA2057456C (fr)
DE (2) DE4100361C1 (fr)
DK (1) DK0493861T3 (fr)
ES (1) ES2097181T3 (fr)
GR (1) GR3022724T3 (fr)
HU (1) HU213112B (fr)
IE (1) IE914477A1 (fr)
NO (1) NO179602C (fr)
PT (1) PT99962B (fr)
ZA (1) ZA9244B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654288A (en) * 1995-01-17 1997-08-05 Birkmayer Pharmaceuticals, Inc. Stable NADH and NADPH compositions for sublingual administration
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2953842A1 (es) * 2023-07-17 2023-11-16 Nuadi Europe S L Tapacubos antipolvo

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3341412A (en) * 1966-03-04 1967-09-12 Enzomedic Lab Inc Methods of treating schizophrenia
CA1336169C (fr) * 1988-03-01 1995-07-04 Walther Birkmayer Agent utilise dans le traitement de la maladie de parkinson

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654288A (en) * 1995-01-17 1997-08-05 Birkmayer Pharmaceuticals, Inc. Stable NADH and NADPH compositions for sublingual administration
US5750512A (en) * 1995-01-17 1998-05-12 Birkmayer Pharmaceuticals, Inc. NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration
US5952312A (en) * 1995-01-17 1999-09-14 Birkmayer Pharmaceuticals, Inc. NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension

Also Published As

Publication number Publication date
EP0493861B1 (fr) 1997-02-19
NO179602C (no) 1996-11-13
AU631755B2 (en) 1992-12-03
AU9010991A (en) 1992-07-16
DE59108553D1 (de) 1997-03-27
HU213112B (en) 1997-02-28
JP2519148B2 (ja) 1996-07-31
ATE148991T1 (de) 1997-03-15
PT99962A (pt) 1993-02-26
DK0493861T3 (da) 1997-08-25
ES2097181T3 (es) 1997-04-01
PT99962B (pt) 1999-06-30
HU9200025D0 (en) 1992-03-30
EP0493861A3 (en) 1993-03-03
GR3022724T3 (en) 1997-06-30
HUT60141A (en) 1992-08-28
EP0493861A2 (fr) 1992-07-08
ZA9244B (en) 1992-10-28
NO179602B (no) 1996-08-05
NO920056L (no) 1992-07-06
DE4100361C1 (fr) 1992-04-23
CA2057456C (fr) 1996-02-06
JPH05139978A (ja) 1993-06-08
NO920056D0 (no) 1992-01-03
BR9105183A (pt) 1992-09-29
IE914477A1 (en) 1992-07-15

Similar Documents

Publication Publication Date Title
CA2170647A1 (fr) Forme posologique sous forme de comprime composite (i)
CA2166483A1 (fr) Nouvelle formulation pharmaceutique
CA2123160A1 (fr) Formulation a liberation controlee
CA2194167A1 (fr) Produit stimulant la pousse des cheveux
CA2029524A1 (fr) Administration transdermique de la 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
EP0645136A3 (fr) Préparation pharmaceutique du type: substance physiologiquement active à libération prolongée.
CA2154424A1 (fr) 1-phenyl-3-dimethylaminopropane possedant des proprietes pharmaceutiques
AU7338791A (en) Medical valve
CA2254833A1 (fr) Produit pharmaceutique pour le traitement de troubles neurologiques et neuropsychiatriques
CA2264097A1 (fr) Emploi du chelateur clioquinol pour produire une preparation pharmaceutique traitant la maladie d'alzheimer
CA2212058A1 (fr) Preparation et utilisation d'un ligand specifique du recepteur gaba-a.alpha.5 destine au traitement de la maladie d'alzheimer
CA2125662A1 (fr) Systeme a administration transdermique contenant de l'acide acetylsalicylique pour le traitement de la thrombose et la prophylaxie du cancer
AU7060896A (en) Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
DE69631609D1 (en) Tricyclische erythromycinderivate
AU2710892A (en) Cytotoxic bicyclo (7.3.1) tridec-4-ene-2,6-diyne compounds and process for the preparation thereof
CA2041417A1 (fr) Traitement d'une maladie du pancreas a l'aide de composes de 15-ceto-prostaglandine
AU6682298A (en) Use of r-nsaid's for the prevention of alzheimer's disease
CA2118030A1 (fr) Medicament servant a elever la concentration de testosterone dans l'organisme
CA2046069A1 (fr) Traitement des maladies inflammatoires au moyen de composes de 15-cetoprostaglandine
CA2301706A1 (fr) Utilisation de phanquinone dans le traitement de la maladie d'alzheimer
AU3728095A (en) Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis
CA2027814A1 (fr) Traitement d'une maladie hepatobiliaire a base de composes 5-cetoprostaglandin
AU4556096A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use as a medicament or diagnostic, and medicament containing them
USD321055S (en) Caliper for dental implants
CA2057456A1 (fr) Produit pharmaceutique contre la depression

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed